Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Moderna (NASDAQ:MRNA) had its price objective upped by equities research analysts at The Goldman Sachs Group from $36.00 to $41.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would indicate a potential downside of 12.02% from the stock’s current price.

Other research analysts also recently issued research reports about the company. TD Cowen reiterated a “hold” rating on shares of Moderna in a report on Thursday, January 29th. Berenberg Bank set a $28.00 price target on Moderna in a research note on Monday, November 17th. Piper Sandler reissued an “overweight” rating on shares of Moderna in a research report on Monday, December 1st. UBS Group restated a “neutral” rating and set a $36.00 target price on shares of Moderna in a report on Monday. Finally, Wall Street Zen raised shares of Moderna from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Two analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $31.47.

Moderna Trading Up 6.1%

NASDAQ:MRNA opened at $46.60 on Tuesday. The company has a 50-day moving average price of $38.21 and a 200-day moving average price of $30.15. The stock has a market cap of $18.21 billion, a price-to-earnings ratio of -6.41 and a beta of 1.32. The company has a current ratio of 3.29, a quick ratio of 3.22 and a debt-to-equity ratio of 0.07. Moderna has a 12 month low of $22.28 and a 12 month high of $55.20.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.79) by $0.68. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The company had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. During the same period in the prior year, the firm earned ($2.91) earnings per share. Moderna’s revenue was down 33.2% on a year-over-year basis. Equities analysts predict that Moderna will post -9.61 EPS for the current year.

Insider Activity

In other news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the sale, the director owned 3,924 shares in the company, valued at $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 10.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MRNA. Rothschild Investment LLC lifted its holdings in shares of Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after buying an additional 446 shares during the period. Atlantic Union Bankshares Corp purchased a new position in Moderna during the second quarter valued at $26,000. Whittier Trust Co. bought a new stake in Moderna during the second quarter valued at about $28,000. MUFG Securities EMEA plc purchased a new stake in Moderna in the second quarter worth about $28,000. Finally, Flagship Harbor Advisors LLC bought a new stake in Moderna during the 4th quarter worth approximately $31,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA accepted Moderna’s revised application and will initiate review of mRNA-1010 with an Aug. 5, 2026 PDUFA date; Moderna proposed an age‑based approval pathway (full approval for adults 50–64, accelerated approval for 65+) which could speed rollout for the 2026–27 flu season. Read More.
• Positive Sentiment: Market reaction: multiple outlets report a share pop after the review decision, reflecting investor optimism about near‑term commercial upside if approved. Read More.
• Positive Sentiment: Clinical pipeline momentum: a mid‑stage trial of a combo flu/COVID mRNA vaccine showed robust immune responses and no safety signals — supportive for Moderna’s broader respiratory vaccine strategy. Read More.
• Positive Sentiment: European expansion: the European Commission granted marketing authorization for Moderna’s COVID vaccine mNEXSPIKE, strengthening its respiratory portfolio in Europe. Read More.
• Neutral Sentiment: Analyst view: Goldman Sachs raised its price target to $41 but kept a “neutral” rating — a modest positive to guidance but still implies limited near‑term upside per that shop. Read More.
• Neutral Sentiment: Regulatory uncertainty remains: the FDA’s earlier refusal and the public debate around it show there is still execution risk and potential delays until the Aug. decision. Read More.
• Negative Sentiment: Legal risk: a court recently rejected two Moderna defenses in its patent dispute with Arbutus, keeping intellectual‑property exposure and potential liabilities on the table. Read More.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.